Meta-analysis: Rapid infliximab infusions are safe

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 4, 2013, Pages 365-376

  Neef, H C ^a   Riebschleger, M P ^a   Adler, J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOMODULATING AGENT; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; STEROID;

ARTICLE; DRUG DOSE COMPARISON; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; HUMAN; INFUSION RELATED REACTION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; QUALITY OF LIFE; RISK FACTORS; SPONDYLARTHROPATHIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880273697     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12389     Document Type: Article

References (32)

1. Feagan BG, Reinisch W, Rutgeerts P, et al,. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
2. Feldman SR, Gordon KB, Bala M, et al,. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Brit J Dermatol 2005; 152: 954-60.
3. Maini R, St Clair EW, Breedveld F, et al,. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
5. Hyams J, Crandall W, Kugathasan S, et al,. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73.
6. Adler J, Sandberg KC, Shpeen BH, et al,. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease J Pediatr Gastroenterol Nutr 2013; 57: 35-8.
7. Remicade (Infliximab) prescribing information [package insert]. Horsham, PA: Janssen Biotech, Inc., 2013.
8. Ollendorf DA, Lidsky L,. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006; 13: 502-6.
9. Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S,. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. JMCP 2011; 17: 313-20.
10. Van Assche G, Lewis JD, Lichtenstein GR, et al,. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106: 1594-602.
11. Behm BW, Bickston SJ,. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 1: CD006893.
12. Rutgeerts P, Feagan BG, Lichtenstein GR, et al,. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
13. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
14. Jacobstein DA, Markowitz JE, Kirschner BS, et al,. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11: 442-6.
15. Befrits R, Malmström L, Forsell A, Bark L-Å, Blomquist L,. One hour infiximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years. Gastroenterology 2008; 134: A402.
16. Belhassan M, Zeitoun JD, Lefevre JH, et al,. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer? Clin Res Hepatol Gastroenterol 2013; 37: 189-92.
17. El Miedany Y, Palmer D,. Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach. Rheumatology (Oxford) 2011; 50: 97-97.
18. Rojany M, Wegelin J, Trudeau W, Prindiville T,. A rapid one-hour infusion of infliximab is well-tolerated gastroenterology. Gastroenterology 2006; 130: A212.
19. Saxena P, Ly C, Leong RW,. Accelerated infliximab infusion protocols are safe. Gastroenterology 2011; 140: S276.
20. Shergy WJ, Isern RA, Cooley DA, et al,. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29: 667-77.
21. Bañuelos-Ramírez D, Ramirez-Palma MM, Balcazar-Sanchez ME, Sanchez-Alonso S,. Rapid application of infliximab. Efficacy complications. Reumatol Clin 2007; 3: 171-5.
22. Bhat S, Sharma D, Doherty P, Tham TC, Caddy GR,. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010; 16: 1922-5.
23. Breynaert C, Ferrante M, Fidder H, et al,. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011; 106: 778-85.
24. Buch MH, Bryer D, Lindsay S, Rees-Evans B, Fairclough A, Emery P,. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006; 45: 485-6.
25. Clare DF, Alexander FC, Mike S, et al,. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21: 71-5.
26. Lee TW, Singh R, Fedorak RN,. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2011; 34: 181-7.
27. Yeckes AR, Hoffenberg EJ,. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49: 151-4.
28. Stroup DF, Berlin JA, Morton SC, et al,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
29. Wells GA, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed March 28, 2013.
30. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
31. Kane SV, Chao J, Mulani PM,. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009; 26: 936-46.
32. Carter CT, Waters HC, Smith DB,. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther 2011; 28: 671-83.